AARTIDRUGS

Aarti Drugs Ltd.

NSE: AARTIDRUGS

BSE: 524348

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

422.30+2.5 (+0.61%)

17 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

67.6 / 100

Value Score

68.6 / 100

Price Momentum Score

49.8 / 100

QVM Score

72.6 / 100

Key Metrics

Market Cap

3854.33

P/E (TTM)

19.77

P/B

2.49

P/S (TTM)

1.50

EV/EBITDA

14.25

CAPE (5Y)

21.45

ROE (TTM)

13.36

ROCE (TTM)

11.79

ROA (TTM)

7.23

Avg 3Y ROE

13.30

Earnings 3Y CAGR

5.95

Sales 3Y CAGR

-1.89

Sales 5Y CAGR

3.55

Debt/Equity

0.37

Consensus TP

439.00

Strong Buy %

Promoter Holding

55.03

Pledged %

2.47

Stock Analysis

Fundamental analysis overview of Aarti Drugs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is reasonably valued and PE TTM is at a discount to industry median

PE TTM of 19.77 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -35.98%

What is P/E Ratio?

Median: 30.88

Value 19.77

-44.893379.36

Moderate EPS growth and above median growth of industry

The company delivered moderate EPS growth of 16.4% for 12-month ended 31 Mar 2026 and the growth was 8.28 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.37 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.08 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 9 financial years

What is Dividend streak?

Negative

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -23.69% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Low but stable operating margin

The company reported low operating margin of 9.44% for 12-month ended 31 Mar 2026 and operating margin declined marginally by -25 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 7.47% for 12-month ended 31 Mar 2026 and the growth was 3.76 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.23

Value 7.47

-82.35114662

Low dividend yield

The company has a low dividend yield of 0.47%

What is Dividend yield?

Neutral

Moderate and stable ROE

The company reported moderate ROE of 13.36% for 12-month ended 31 Mar 2026 and ROE improved marginally by 67 bps from 1 year ago

What is ROE (FY)?

Company's earnings are of moderate quality

Earnings quality score of 64.6 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

64.6 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Aarti Drugs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Aarti Drugs Ltd. Shareholding Pattern

Quarterly breakdown of Aarti Drugs Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	61.44	60.51	60.21	60.20	60.20	60.14	60.12	59.99	59.83	59.98	59.77	59.66	59.58	58.70	58.56	57.47	57.13	55.67	55.64	55.38	55.48	55.22	54.72	55.03	55.03
Indian Promoter	61.44	60.51	60.21	60.20	60.20	60.14	60.12	59.99	59.83	59.98	59.77	59.66	59.58	58.70	58.56	57.47	57.13	55.67	55.64	55.38	55.48	55.22	54.72	55.03	55.03
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	5.89	6.91	4.34	4.74	4.75	4.57	4.33	4.31	4.76	4.83	5.10	5.80	6.03	6.67	7.64	7.36	8.55	10.31	10.34	11.05	11.95	12.19	12.59	12.27	11.80
Mutual Funds / UTI	4.19	4.49	1.85	1.50	1.59	1.85	2.05	2.20	2.62	2.68	3.08	3.82	4.01	4.63	5.22	5.18	5.08	5.70	6.25	7.78	8.75	9.85	9.81	10.03	10.14
FI/Bank/Insurance	0.11	0.03	0.00	0.02	0.00	0.12	0.04	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.10	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	1.07	1.82	2.19	3.06	2.99	2.57	2.21	2.03	2.07	2.07	1.94	1.90	1.94	1.97	2.33	2.10	2.56	2.95	2.50	2.28	2.25	2.26	2.68	2.15	1.57
Other Institutions	0.52	0.57	0.30	0.15	0.17	0.03	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.83	1.57	1.50	0.91	0.87	0.01	0.01	0.01	0.00
Non-Institution	32.67	32.58	35.45	35.07	35.05	35.29	35.55	35.71	35.41	35.19	35.13	34.54	34.39	34.62	33.79	35.17	34.31	34.02	34.02	33.57	32.57	32.58	32.69	32.70	33.18
Bodies Corporate	1.57	1.79	1.50	1.03	0.84	0.67	0.58	0.50	0.75	0.74	0.47	0.57	0.51	1.06	1.01	1.15	1.08	1.21	1.06	1.04	0.96	0.81	0.86	0.90	1.02
Others (incl. Retail) No. of shareholders	31.10 18,933	30.79 22,849	33.95 1,04,965	34.04 1,50,622	34.21 1,73,111	34.62 1,77,425	34.97 1,82,823	35.21 1,94,969	34.66 1,89,132	34.45 1,86,191	34.66 1,79,790	33.97 1,72,782	33.88 1,68,636	33.56 1,61,919	32.78 1,66,932	34.02 1,69,900	33.23 1,56,924	32.81 1,49,532	32.96 1,89,573	32.53 1,75,340	31.61 1,69,145	31.77 1,59,812	31.83 1,51,781	31.80 1,47,917	32.16 1,44,482

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Microcap 250	0.15%	223 / 250
2	Nifty Total Market	0.01%	722 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Aarti Drugs Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Seema Harshit Savla Promoter Group	April-2022	Market Purchase (Acquisition) 3rd Apr 2022	4.92 %	₹ 440.78	11.00 k	₹ 48.49 lac
Harshit Manilal Savla Promoter & Director	April-2022	Market Purchase (Acquisition) 3rd Apr 2022	4.73 %	₹ 440.78	14.00 k	₹ 61.71 lac
Harit Pragji Shah Director	April-2022	Market Purchase (Acquisition) 3rd Apr 2022	2.65 %	₹ 440.78	25.00 k	₹ 1.10 cr
Prakash Moreshwar Patil Promoter & Director	April-2022	Market Purchase (Acquisition) 3rd Apr 2022	9.15 %	₹ 440.73	50.00 k	₹ 2.20 cr
ALCHEMIE FINSERV PRIVATE LIMITED Promoter Group	April-2022	Market Purchase (Acquisition) 3rd Apr 2022	2.07 %	₹ 437.21	53.50 k	₹ 2.34 cr
Renil Rajendra Gogri Promoter Group	April-2022	Market Sale (Disposal) 3rd Apr 2022	1.93 %	₹ 438.13	1.65 lac	₹ 7.21 cr
Renil Rajendra Gogri Promoter Group	April-2022	Market Sale (Disposal) 1st Apr 2022	2.13 %	₹ 439.28	1.81 lac	₹ 7.93 cr
ALCHEMIE FINSERV PRIVATE LIMITED Promoter Group	April-2022	Market Purchase (Acquisition) 1st Apr 2022	2.00 %	₹ 438.95	70.00 k	₹ 3.07 cr
RASHESH CHANDRAKANT GOGRI Promoter & Director	April-2022	Market Purchase (Acquisition) 1st Apr 2022	4.52 %	₹ 440.54	1.20 lac	₹ 5.29 cr
Arun Moreshwar Patil Promoter Group	March-2022	Market Purchase (Acquisition) 8th Mar 2022	0.07 %	₹ 459.35	609.00	₹ 2.80 lac

…

Corporate Actions

History of Aarti Drugs Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 2/share
Record date: 9th Feb 2026Ex-date: 9th Feb 2026
Announced on: 3rd Feb 2026
Dividend₹ 1/share
Record date: 4th Feb 2025Ex-date: 4th Feb 2025
Announced on: 29th Jan 2025
Others
Ex-date: 5th Sep 2024Announced on: 26th Sep 2024
"On Market tender offer.Open Market Purchase. As of 26 September 2024Shares Repurchased 665000. Total Amount Returned INR 598500000. Share capital 0.72 percent…
Dividend₹ 1/share
Record date: 6th Feb 2024Ex-date: 6th Feb 2024
Announced on: 24th Jan 2024
Others
Ex-date: 4th Aug 2023Announced on: 21st Jul 2023
"On Market Tender Offer. Total Amount Returned INR 598500000. As of 01 September 2023 Shares repurchased 665000."

Company Profile

Overview of Aarti Drugs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India....

Key personnel

Shri. Adhish P. Patil

Chief Financial Officer, Chief Operating Officer

Mr. Rushikesh Vivek Deole

Compliance Officer, Company Secretary

Shri. Prakash M. PatilD

Chairman of the Board, Chief Executive Officer, Managing Director, Executive Director

Mr. Chandrakant Vallabhaji GogriD

Chairman Emeritus

Shri. Harshit Manilal SavlaD

Joint Managing Director, Executive Director

Shri. Rashesh Chandrakan GogriD

Managing Director, Executive Director

Shri. Uday Moreshwar PatilD

Executive Director

Shri. Harit Pragji ShahD

Executive Director

View all

Incorporated on

28 Sep 1984

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

12 May 1993

Free Float

3,63,54,093

Website

https://www.aartidrugs.co.in/

Phone no.

+912224019025

Address

MAHENDRA INDUSTRIAL ESTATE, GROUND FLOOR, PLOT NO. 109-D, ROAD NO 29, SION (EAST), MUMBAI, , 400022, India

Frequently Asked Questions

What is the current share price of Aarti Drugs Ltd.?

The current share price of Aarti Drugs Ltd. is ₹ 422.30 as of 17 Jul 2026.

What is the market capitalisation of Aarti Drugs Ltd.?

The market capitalisation of Aarti Drugs Ltd. stands at ₹ 3,854.33 Cr.

What is the PE ratio of Aarti Drugs Ltd.?

The Price-to-Earnings (PE) ratio of Aarti Drugs Ltd. is 19.77 as of the latest trailing twelve months data.

What is the ROE and ROCE of Aarti Drugs Ltd.?

Aarti Drugs Ltd. has a Return on Equity (ROE) of 13.36% and a Return on Capital Employed (ROCE) of 11.79% as per the latest financial reports.

What is the 52-week high and low of Aarti Drugs Ltd.?

The 52-week high of Aarti Drugs Ltd. is - and the 52-week low is -.

What is the dividend yield of Aarti Drugs Ltd.?

The dividend yield of Aarti Drugs Ltd. is 0.47% based on the current market price.

What is the FII and DII holding in Aarti Drugs Ltd.?

Foreign Institutional Investors (FII) hold 1.57%, Domestic Institutional Investors (DII) hold 10.22% and retail/public investors hold 32.16% of Aarti Drugs Ltd. shares.

What sector does Aarti Drugs Ltd. belong to?

Aarti Drugs Ltd. operates in the Healthcare sector.

What is the beta of Aarti Drugs Ltd.?

The beta of Aarti Drugs Ltd. is 0.97, indicating its price volatility relative to the broader market. Over the past 1 year, Aarti Drugs Ltd. has delivered an absolute return of -11.53%.

What is the RSI of Aarti Drugs Ltd.?

The 14-day Relative Strength Index (RSI) of Aarti Drugs Ltd. is 74.76, placing it in the overbought zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Aarti Drugs Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Aarti Drugs Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Company Profile

Corporate Actions